| Next 10 |
Ad
BPMC News and Press Blueprint Medicines Corporation
-
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire -- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE...
-
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai , M.D., to its board of directors. D...
-
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale PR Newswire -- Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million -- ...
-
Summary Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline. The price response to these updates hasn't held into the final stages of the year, however. There are multiple inflectio...
-
Summary Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities. Also, the in-house pipeline is set t...
-
Blueprint Medicines ( NASDAQ: BPMC ) reported long term updated of Ayvakit from the PATHFINDER and EXPLORER trials in patients with advanced systemic mastocytosis (SM) and part of 1 of the HARBOR study of elenestinib. Ayvakit is approved in the US. to treat ...
-
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAM...
-
Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting PR Newswire CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acce...
-
Oppenheimer downgraded Blueprint Medicines Corporation ( NASDAQ: BPMC ) to Perform from Outperform at Oppenheimer on Wednesday, noting challenges in the rollout of the biotech's cancer therapy Ayvakit. In January 2020, the FDA approved Ayvakit for certain patients with met...
-
Blueprint Medicines press release ( NASDAQ: BPMC ): Q3 GAAP EPS of -$2.23 beats by $0.28 . Revenue of $65.97M (+172.7% Y/Y) beats by $22.09M . GUIDANCE: Blueprint Medicines anticipates it will achieve the high end of previously provided revenue guidance for ful...
Stock Information
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Get BPMC Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
